SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Aigner Clemens)
 

Sökning: WFRF:(Aigner Clemens) > Potential subtype-s...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00003397naa a2200349 4500
001oai:lup.lub.lu.se:128947c3-7e30-4c39-807f-778fbcd79cfa
003SwePub
008240131s2024 | |||||||||||000 ||eng|
024a https://lup.lub.lu.se/record/128947c3-7e30-4c39-807f-778fbcd79cfa2 URI
024a https://doi.org/10.1097/CCO.00000000000010052 DOI
040 a (SwePub)lu
041 a engb eng
042 9 SwePub
072 7a for2 swepub-publicationtype
072 7a ref2 swepub-contenttype
100a Horvath, Lillau National Korányi Institute for Tuberculosis and Pulmonology, Hungary4 aut
2451 0a Potential subtype-specific therapeutic approaches in small cell lung cancer
264 1c 2024
300 a 6 s.
520 a PURPOSE OF REVIEW: Small cell lung cancer (SCLC) remains one of the most aggressive thoracic malignancies with an especially dismal prognosis. While the detection of various targetable driver mutations and immune checkpoints have revolutionized the treatment of non-small cell lung cancer (NSCLC), there has been only modest therapeutic innovation over the past decades in SCLC. In this review, we aim to provide a brief summary on the clinical relevance of recent research findings, which could soon pave the way towards a more personalized and targeted management of SCLC patients. RECENT FINDINGS: Substantial research on the biological and molecular heterogeneity of SCLC has been conducted in the last years. Recent results from comprehensive profiling studies have shown that unique major SCLC subtypes can be distinguished based on the relative expression of key transcription regulators (ASCL1, NEUROD1, POU2F3) or distinct inflammatory features. Understanding the differing molecular characteristics of these distinct subtypes has resulted in the identification of specific therapeutic vulnerabilities. SUMMARY: The recently introduced molecular SCLC subtype classification represents a substantial progress towards a personalized and more efficacious approach in SCLC. The consequences of this paradigm shift provide hope for improved patient care and clinical outcomes in this exceptionally lethal thoracic malignancy.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng
700a Lang, Christianu Medical University of Vienna4 aut
700a Boettiger, Kristiina4 aut
700a Aigner, Clemens4 aut
700a Dome, Balazsu Lund University,Lunds universitet,Klinisk kemi, Malmö,Forskargrupper vid Lunds universitet,Clinical Chemistry, Malmö,Lund University Research Groups,Semmelweis University,National Korányi Institute for Tuberculosis and Pulmonology, Hungary4 aut0 (Swepub:lu)ba1464do
700a Megyesfalvi, Zsoltu National Korányi Institute for Tuberculosis and Pulmonology, Hungary,National Institute of Oncology, Budapest4 aut
710a National Korányi Institute for Tuberculosis and Pulmonology, Hungaryb Medical University of Vienna4 org
773t Current Opinion in Oncologyg 36:1, s. 51-56q 36:1<51-56x 1040-8746
856u http://dx.doi.org/10.1097/CCO.0000000000001005y FULLTEXT
8564 8u https://lup.lub.lu.se/record/128947c3-7e30-4c39-807f-778fbcd79cfa
8564 8u https://doi.org/10.1097/CCO.0000000000001005

Hitta via bibliotek

Till lärosätets databas

Sök utanför SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy